Evidence map›Paper›PMID 27025911›Full record

SynthesisScientific reports2016

Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3,430 patients.

Xiaobin Gu, Shaoqian Sun, Xian-Shu Gao, Wei Xiong, Shangbin Qin, Xin Qi, Mingwei Ma, Xiaoying Li, Dong Zhou, Wen Wang and 1 more

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xiaobin GuDepartment of Radiation Oncology, Peking University First Hospital, Beijing 100034, China.
Shaoqian SunDepartment of Radiation Oncology, Peking University First Hospital, Beijing 100034, China.
Xian-Shu GaoDepartment of Radiation Oncology, Peking University First Hospital, Beijing 100034, China.
Wei XiongTangshan People's Hospital, Hebei 063000, China.
Shangbin QinDepartment of Radiation Oncology, Peking University First Hospital, Beijing 100034, China.
Xin QiDepartment of Radiation Oncology, Peking University First Hospital, Beijing 100034, China.
Mingwei MaDepartment of Radiation Oncology, Peking University First Hospital, Beijing 100034, China.
Xiaoying LiDepartment of Radiation Oncology, Peking University First Hospital, Beijing 100034, China.
Dong ZhouDepartment of Radiation Oncology, Peking University First Hospital, Beijing 100034, China.
Wen WangDepartment of Radiation Oncology, Peking University First Hospital, Beijing 100034, China.
Hao YuDepartment of Radiation Oncology, Peking University First Hospital, Beijing 100034, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study was designed to explore the association between elevated platelet to lymphocyte ratio (PLR) and prognosis of patients with non-small cell lung cancer (NSCLC) by meta-analysis. A total of 11 studies with 3,430 subjects were included and the combined hazard ratio (HR) and 95% confidence intervals (95% CI) were calculated. The data showed that elevated PLR predicted poor overall survival (OS) (HR = 1.42; 95% CI: 1.25-1.61, p < 0.001; I(2) = 63.6, Ph = 0.002) and poor disease-free survival (DFS)/progression-free survival (PFS) (HR = 1.19; 95%CI: 1.02-1.4, p = 0.027; I(2) = 46.8, Ph = 0.111). Subgroup analysis showed elevated PLR did not predict poor OS in patients included in large sample studies (HR = 1.44; 95% CI: 0.94-2.21, p = 0.098) whereas patients with Caucasian ethnicity (HR = 1.59; 95%CI: 1.27-1.98, p < 0.001) and PLR cut-off value > 180 (HR = 1.61; 95%CI: 1.3-1.99, p < 0.001) had enhanced prognostic efficiency for OS. Subgroup analysis also demonstrated that high PLR did not predict poor DFS/PFS in Asian patients. In conclusion, our meta-analysis suggested that elevated PLR was associated with poor OS and DFS/PFS in NSCLC. In addition, high PLR especially predicted poor OS in Caucasians but had no association with poor DFS/PFS in Asians.

Indexed as

Carcinoma, Non-Small-Cell LungDisease-Free SurvivalHumansLung NeoplasmsLymphocyte CountPlatelet CountPrognosisProportional Hazards Models

Identifiers

PMID27025911
PMCPMC4812293

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.